Helius Medical Technologies, Inc. (HSDT)
| Market Cap | 2.80M |
| Revenue (ttm) | 502,000 |
| Net Income (ttm) | -8.86M |
| Shares Out | 3.73M |
| EPS (ttm) | -4.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 379,472 |
| Open | 0.807 |
| Previous Close | 0.803 |
| Day's Range | 0.740 - 0.808 |
| 52-Week Range | 0.373 - 9.500 |
| Beta | 1.48 |
| Analysts | Buy |
| Price Target | 24.00 (+3,095.74%) |
| Earnings Date | Nov 12, 2024 |
About HSDT
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company’s product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. Heliu... [Read more]
Financial Performance
In 2023, HSDT's revenue was $644,000, a decrease of -18.17% compared to the previous year's $787,000. Losses were -$8.85 million, -37.11% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for HSDT stock is "Buy." The 12-month stock price forecast is $24.0, which is an increase of 3,095.74% from the latest price.
News
Helius Announces First Portable Neuromodulation Stimulator (PoNS®) System Sale to the Veterans Affairs (VA) Healthcare System
Initial order placed with Company's distributor at contracted price and represents operational implementation through VA Federal Supply Schedule (FSS) Contract Initial order placed with Company's dist...
Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device
NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulati...
Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece
-- Reimbursement Determination for the PoNS Mouthpiece (HCPCS code A4594) set at $2,963.30 on Lump Sum Payment to be challenged by Helius -- -- National Reimbursement Payment Determination from CMS fo...
Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
NEWTOWN, Pa., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that...
Helius Medical Technologies, Inc. (HSDT) Q2 2024 Earnings Call Transcript
Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Michelle Bilski - IR Dane Andreeff - President and CO Jeff Mathiesen - ...
Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results
NEWTOWN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulati...
Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024
NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulat...
Helius Medical Technologies, Inc. Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke
-- Inclusion of the top neurorehabilitation centers REHABOLOGYM, Neurology Center of New England, and MGH Institute of Health Professions completes site participation enrollment for the U.S. registrat...
Helius Medical Technologies, Inc. to Present at the Spring MicroCap Rodeo Conference
NEWTOWN, PA / ACCESSWIRE / May 31, 2024 / Helius Medical Technologies, Inc., (Nasdaq:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation ap...
Helius Medical Technologies to Exhibit at 2024 CMSC Annual Meeting, Marking a Year of Achievements: Making PoNS More Available to People with MS
Company Will Highlight Major Milestones on Accessibility and Reimbursement Fronts Company Will Highlight Major Milestones on Accessibility and Reimbursement Fronts
Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts
-- Approval provides U.S. veterans and other U.S. government agency employees who suffer gait and balance impairment due to multiple sclerosis (MS) access to the only portable neurostimulation therapy...
Helius Medical Technologies, Inc. (HSDT) Q1 2024 Earnings Call Transcript
Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q1 2024 Results Conference Call May 13, 2024 4:30 PM ET Company Participants Michelle Bilski - Investor Relations-In-Site Communications Dane Andreeff ...
Helius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results
NEWTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulatio...
Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024
NEWTOWN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulati...
Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering
NEWTOWN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulati...
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center
-- Helius Medical and Shepherd Center partner on a study that aims at rehabilitating walking mobility in people recovering from stroke -- -- Shepherd Center, a top neurorehabilitation hospital, is the...
Helius Medical stock rallies 40%: explore why
Helius Medical Technologies Inc (NASDAQ: HSDT) is up close to 40% in premarket on Wednesday after teaming up with Lovell Government Services. Why is it good news for Helius Medical stock?
Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
-- Lovell is an approved supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) -- -- Over 28,000 cases of multiple sclerosis (MS) are reported to the VA annually -- ...
Helius Medical Technologies, Inc. (HSDT) Q4 2023 Earnings Call Transcript
Helius Medical Technologies, Inc. (HSDT) Q4 2023 Earnings Call Transcript
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
-- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on ...
Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
NEWTOWN, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodula...
Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke
-- Enrollment of at least ten patients at Brooks Rehabilitation will begin this month -- -- Study will evaluate the use of Portable Neuromodulation Stimulator (PoNS®) for gait and balance deficits in ...
Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference
NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulat...
Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller
-- Significant step toward reimbursement for the only medical device approved in the U.S. for treatment of gait deficit due to multiple sclerosis (“MS”) -- -- Proceeds from recent stock issuances thro...
Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients
-- Studies uses Portable Neuromodulation Stimulator (PoNS®) to evaluate cranial-nerve non-invasive neuromodulation for gait/balance deficits in stroke patients -- -- Interaction with FDA on clinical p...